Erratum to: Cancer Chemother Pharmacol DOI 10.1007/s00280-016-2985-y
Unfortunately, the online published article has error in Table 5. The correct Table 5 is given here. The original article has been corrected.
Table 5.
Docetaxel, CDDP, and 5-Fu for advanced esophageal cancer
| References (first author) | Target | Regimen (/m2) | Phase | Cases, n | Grade 3/4 leukopenia (%) | Grade 3/4 neutropenia (%) | Febrile neutropenia (%) | Response rate (%) | Histopathological response rate (>grade 2) (%) | Histopathological complete response rate (grade 3) (%) | Dose reduction rate in the second cycle (%) | Protocol completion rate (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takahashi [32] | Esophageal cancer (SCC) Stages III, IV |
D: 50 (day 1) C: 70 (day 1) F: 700 (days 1–5)/3 wks |
I/II | 39 | 53.8 | 43.6 | 12.8 | 66.6 | – | – | – | – |
| Osaka [33] | Esophageal cancer (SCC) Stages III, IV |
D: 60 (day 1) C: 60 (day 1) F: 800 (days 1–5)/3–4 wks × 2 courses |
II | 30 | 33.3 | – | – | 83.3 (primary lesion) | – | – | – | 96.7 |
| Yamasaki [23] | Esophageal cancer (SCC) Stages III, IV |
D: 70 (day 1) C: 70 (day 1) F: 700 (days 1–5)/3 wks × 2 courses |
I/II | 9/40 | 72.5 | 90 | 10 | 72.5 | 40 | 25 | – | 82.5 |
| Tamura [34] | Esophageal cancer (SCC) Stage IV |
D: 60 (day 1) C: 70 (day 1) F: 600 (days 1–5)/4 wks × 2 courses |
II | 29 | 52 | 76 | 21 | 34.5 (confirmed cases) | – | – | 13.8 | – |
| Ferri [35] | Esophageal cancer and gastric cancer (AD) Stages II, III, IV |
D: 75 (day 1) C: 75 (day 1) F: 750 (days 1–5)/3 wks × 3 courses |
II | 43 | – | 20 | 2.3 | – | – | 9.8 | – | 95 |
| Hara [36] | Esophageal cancer (SCC) Stages IIA, IIB, III |
D: 70 (day 1) C: 70 (day 1) F: 750 (days 1–5) D: 75 (day 1) C: 75 (day 1) F: 750 (days 1–5)/3 wks × 3 courses |
II | 42 | 45.2 | 83.3 | 2.4 | 64.3 | 51 | 17 | 64.3 | 95.2 |
| Watanabe [37] | Esophageal cancer (SCC, AD) Stages IIB, III, IVA, IVB (TNM6) |
D: 60 (day 1) C:6 (days 1–5) F: 350 (days 1–5)/3 wks × 2 courses |
Prospective intension-to-treat | 50 | – | 78.2 | 14.5 | 53.7 | 26 | 12 | – | – |
| Hironaka [38] | Esophageal cancer (SCC, AS, B) Stage IV |
D: 30 (days 1, 15) C: 80 (day 1) F: 800 (days 1–5)/4 wks |
I/II | 10/52 | 9.1 | 25.5 | 0 | 62 | – | – | – | – |
| Current study | Esophageal cancer (SCC) Stages II, III |
D: 35 (days 1, 15) C:40 (days 1, 15) F: 400 (days 1–5, 15–19) |
II | 32 | 12.5 | 31.3 | 0 | 90.3 | 53.2 | 21.9 | 0 | 100 |
SCC squamous cell carcinoma, AD adenocarcinoma, AS adenosquamous carcinoma, B basaloid carcinoma, D docetaxel, C cisplatin, F fluorouracil
Footnotes
The online version of the original article can be found under doi:10.1007/s00280-016-2985-y.